9 studies were found.

1.		No longer recruiting	Combination Chemotherapy Following Surgery in Treating Women With Early Stage Breast Cancer Conditions: stage II breast cancer; stage IIIA breast cancer
2.		No longer recruiting	Combination Chemotherapy in Treating Women With Breast Cancer Conditions: stage IIIB breast cancer; stage IIIA breast cancer; inflammatory breast cancer
3.		Recruiting	Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer Condition: Neutropenia
4.		No longer recruiting	Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer Conditions: inflammatory breast cancer; stage III breast cancer; Quality of Life
5.		No longer recruiting	Standard Chemotherapy Compared With High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer Conditions: stage IIIA breast cancer; stage II breast cancer
6.		No longer recruiting	Tamoxifen Following Combination Chemotherapy in Treating Women With Operable Invasive Breast Cancer Conditions: stage I breast cancer; stage II breast cancer; stage IIIA breast cancer
7.		No longer recruiting	Tamoxifen With or Without Combination Chemotherapy in Treating Postmenopausal Women With Operable Invasive Breast Cancer Conditions: stage I breast cancer; stage II breast cancer; stage IIIA breast cancer
8.		No longer recruiting	Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer Conditions: stage II breast cancer; stage I breast cancer; stage IIIA breast cancer
9.		No longer recruiting	Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Operable Invasive Breast Cancer Conditions: stage I breast cancer; stage II breast cancer; stage IIIA breast cancer